Rockwell Medical (RMTI) Posts Earnings Results, Misses Estimates By $0.05 EPS

Rockwell Medical (NASDAQ:RMTI) issued its quarterly earnings data on Thursday, March 15th. The company reported ($0.18) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.05), Bloomberg Earnings reports. The company had revenue of $14.84 million for the quarter, compared to the consensus estimate of $13.20 million. Rockwell Medical had a negative return on equity of 61.67% and a negative net margin of 45.24%. The company’s revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.10) earnings per share.

Shares of NASDAQ:RMTI opened at $5.27 on Friday. Rockwell Medical has a 12 month low of $4.84 and a 12 month high of $8.98.

How to Become a New Pot Stock Millionaire

A number of equities analysts recently commented on the stock. BidaskClub raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Friday, December 15th. Zacks Investment Research downgraded shares of Rockwell Medical from a “hold” rating to a “sell” rating in a report on Thursday, January 4th. Finally, ValuEngine cut shares of Rockwell Medical from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd.

TRADEMARK VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/rockwell-medical-rmti-releases-quarterly-earnings-results-misses-estimates-by-0-05-eps.html.

About Rockwell Medical

Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.

Earnings History for Rockwell Medical (NASDAQ:RMTI)

Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply